Biomedical Engineering Reference
In-Depth Information
49. Hinds S, Bian W, Dennis RG, Bursac N (2011) The role of extracellular matrix composition in
structure and function of bioengineered skeletal muscle. Biomaterials 32(14):3575-3583
50. Howard L, Zheng Y, Horrocks M, Maciewicz RA, Blobel C (2001) Catalytic activity of
ADAM28. FEBS Lett 498(1):82-86
51. Van den Hu J, Steen PE, Houde M, Ilenchuk TT, Opdenakker G (2004) Inhibitors of gelatinase B/
matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-
chain derivatives of a neutralizing monoclonal antibody. Biochem Pharmacol 67(5):1001-1009
52. Hubbell J (2006) Matrix-bound growth factors in tissue repair. Swiss Med Wkly 136(25-26):
387-391
53. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph
14(1):33-38, 27-38
54. Hyer S, Wei S, Brew K, Acharya KR (2007) Crystal structure of the catalytic domain of matrix
metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloprotei-
nase-1. J Biol Chem 282(1):364-371
55. Janusz MJ, Hook fi n EB, Brown KK, Hsieh LC, Heitmeyer SA, Taiwo YO et al (2006)
Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metallopro-
teinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflamm Res 55(2):60-65
56. Jayakumar P, Di Silvio L (2010) Osteoblasts in bone tissue engineering. Proc Inst Mech Eng
H 224(12):1415-1440
57. Jones KS (2008) Effects of biomaterial-induced in fl ammation on fi brosis and rejection. Semin
Immunol 20(2):130-136
58. Juliano RL, Haskill S (1993) Signal transduction from the extracellular matrix. J Cell Biol
120(3):577-585
59. Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ (2006) MMP-2 assessment as an
indicator of wound healing: a feasibility study. Adv Skin Wound Care 19(6):324-327
60. Kass L, Erler JT, Dembo M, Weaver VM (2007) Mammary epithelial cell: influence of extra-
cellular matrix composition and organization during development and tumorigenesis. Int J
Biochem Cell Biol 39(11):1987-1994
61. Kataoka H (2009) EGFR ligands and their signaling scissors ADAMs as new molecular targets
for anticancer treatments. J Dermatol Sci 56(3):148-153
62. Khan OF, Jean-Francois J, Sefton MV (2010) MMP levels in the response to degradable
implants in the presence of a hydroxamate-based matrix metalloproteinase sequestering
biomaterial in vivo. J Biomed Mater Res A 93(4):1368-1379
63. Kimata M, Otani Y, Kubota T, Igarashi N, Yokoyama T, Wada N et al (2002) Matrix metallo-
proteinase inhibitor marimastat decreases peritoneal spread of gastric carcinoma in nude mice.
Jpn J Cancer Res 93(7):834-841
64. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y et al (1998) TIMP-2 promotes
activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on
agarose beads. J Biol Chem 273(26):16098-16103
65. Kirkpatrick CJ, Krump-Konvalinkova V, Unger RE, Bittinger F, Otto M, Peters K (2002)
Tissue response and biomaterial integration: the efficacy of in vitro methods. Biomol Eng
19(2-6):211-217
66. Koltsova EK, Ley K (2010) The mysterious ways of the chemokine CXCL5. Immunity
33(1):7-9
67. Kornberg L, Juliano RL (1992) Signal transduction from the extracellular matrix: the integrin-
tyrosine kinase connection. Trends Pharmacol Sci 13(3):93-95
68. Krane SM (1995) Is collagenase (matrix metalloproteinase-1) necessary for bone and other
connective tissue remodeling? Clin Orthop Relat Res (313):47-53
69. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V et al (2001) Hydroxamate-type matrix
metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61(4):1272-1275
70. Kurizaki T, Toi M, Tominaga T (1998) Relationship between matrix metalloproteinase expres-
sion and tumor angiogenesis in human breast carcinoma. Oncol Rep 5(3):673-677
71. Lagente V, Boichot E (2008) Matrix metalloproteinases in tissue remodelling and inflammation.
Birkhäuser, Basel; Boston
Search WWH ::
Custom Search